Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise

Dexcom Inc. Stock

Price
 
€262.80
1.95
0.750%
Target price
€300.00
Latest predictions
€300.00
11.02.20
buy
Your prediction

Dexcom Inc. Stock

The Dexcom Inc. stock is trending slightly upwards today, with an increase of €1.95 (0.750%) compared to yesterday's price.
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Dexcom Inc. stock is not clear.
As a result the target price of €300.00 shows a slightly positive potential of 14.155% compared to the current price of €262.80 for Dexcom Inc..
Register To Post

Other discussions about Dexcom Inc. Stock

New thread

News

Dexcom to Present at Cowen 40th Annual Healthcare Conference


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:




  • Steven Pacelli, Executive Vice President, Strategy

Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System


DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom continuous glucose monitoring systems

Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.



Fourth Quarter 2019 Highlights:




  • Revenue grew 37% versus the

Dexcom Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for February 13, 2020 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2019 financial results after market close on Thursday, February 13, 2020. Management will hold a

Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook


DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be

Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference


DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare

Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:




  • Steven Pacelli, Executive Vice President, Strategy

Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:




  • Steven Pacelli, Executive Vice President, Strategy and

Dexcom Reports Third Quarter 2019 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2019.



Third Quarter 2019 Highlights:




  • Revenue grew 49% versus the same quarter of